Kathleen Moore, MD is Director, Oklahoma TSET Phase I Program; Associate Professor, Section of Gynecologic Oncology and is an associate professor in the section of gynecologic oncology and serves as the director of the Oklahoma TSET Phase I Clinical Trials Program, the state’s only phase I clinical trials program. She is the Jim and Christy Everest Endowed Chair in Cancer Research as well as the director of the gynecologic oncology fellowship program. She also serves as the Associate Director of Clinical Research and Medical Director of the Clinical Trials Office for the Stephenson Cancer Center.
Dr. Moore has published more than 200 peer-reviewed publications and serves on the editorial board for four academic publications. She has a clinical research interest in drug development and phase I trials.
She attended medical school at the University of Washington School of Medicine and completed her residency in obstetrics and gynecology at the University Health Center of Pittsburgh. Dr. Moore completed a fellowship in gynecologic oncology at the University of Oklahoma Health Sciences Center while simultaneously earning a master’s degree in epidemiology..
She is board certified in obstetrics and gynecology as well as gynecologic oncology and hospice and palliative care.
Dr. Moore will discuss the unique concerns of female patients who develop Secondary MDS/AML after chemotherapy treatment. This session will include current treatment options as well as a review of what is currently in clinical trial, including Dr. Moore's own work in drug development.
Participants will be able to ask questions during the live webinar via the text chat window.
Thank you for registering for "Secondary MDS/AML in Women After Chemotherapy" on August 19, 2020 at 4pm EDT/3pm CDT.
You will receive an email with a registration confirmation including the webinar link
and a call-in phone # for those participating via telephone. If you do not receive the link,
please check your Spam/Junk folders.
If you have not received a registration confirmation, please email firstname.lastname@example.org
or call (800) 747-2820 x2 no later than 30 minutes before the webinar is scheduled to begin.
If you are not able to join the webinar, an archived video will be available in 2 - 3 business days on the AAMDSIF website.